



| Mission

We devote all our knowledge to serve people, enabling them to lead long and healthy lives



Tradition, expertise, quality



Foundation of the legal predecessor of Egis by Swiss Dr. Albert Wander and Hungarian Sándor Balla Budapest



Start of galenic products' manufacturing Körmend



Egis became listed on the Budapest Stock Exchange

1913

1950

1976

1989

1994



Commencement of API production Budapest



Start of injection production Budapest



Tradition, expertise, quality



SERVIER


1995

French Servier acquired 51% Stake in Egis

Servier acquired 100% ownership of Egis

Egis launched Europe's first biosimilar monoclonal antibody medicine

2013



Egis strengthened its presence in the OTC market with the acquisition of Biovital in Poland



2015

Modernisation of the active ingredient manufacturing infrastructure started Budapest

The company inaugurated a brand new galenic plant Körmend



2019



2021

Two technology-intensive investments finished in Körmend:

- modernisation of the existing packaging infrastructure (1st phase)
- Inauguration of a plant for finished oncology products with special manufacturing requirements

Vertically integrated leading regional pharmaceutical company



Research and Development

- State-of-the-art research laboratories
- Highly potent active ingredients, value-added generics, branded generics

Contract manufacturing and development

- active ingredients



Active Ingredient and Finished Product Production

- Active ingredient synthesis
- Finished product formulation: tablets, capsules, injections, galenic forms
- Biosimilar: secondary packaging
- Packaging



Sales

- 20% domestic
- 80% export

Egis in numbers



4600

colleagues

100

countries

158

active ingredients

653

products

In the 2022/2023 business year our portfolio consisted of 653 products, belonging to 177 product lines containing 158 active ingredients.

Egis premises in Hungary



◆ Modernising our premises - **430 million EUR** investment in 10 years

Budapest, Keresztúri út
headquarters

1270
colleagues



R&D
HP development centre
Active ingredient production

Budapest, Bökényföldi út
site

830
colleagues



R&D
Finished product production
(tableting/injection plants)
Packaging
Biosimilar secondary packaging

Budapest, Lehel utca
site

570
colleagues



Sales and marketing

Production site of
Körmend

710
colleagues



R&D
Finished product production
(tableting plant/ galenic plant)
HP finished product production
Packaging

9 Innovation Prizes



◆ 1998 - „**Medicine of the year**”
award for our potassium substitute


◆ **8 x Innovation Prize**
1 x Innovation Grand Prize



Regionally outstanding R&D investments*




18,7 billion HUF (48 million EUR)



*based on the „Scoreboard 2023_EU 1000” list, published as a part of The 2023 EU Industrial R&D Investment Scoreboard

2022/2023 business year, data not audited


Main therapeutic areas



2022/2023 business year, based on turnover of human drug sales; data not audited



More than 30 million patients are treated yearly with Egis medicines



more than
1000 tons
active ingredients/
intermediates




6 billion
tablets and capsules
76% of the world population



193 million
boxes of drugs sold ...

Buenos Aires - Budapest – Tokyo
...the length of the chain of boxes

Turnover by regions




631.7 million EUR turnover

Egis in the world



Egis products reach
100 countries

€ 631.7 million
turnover in 2022/2023



18 countries,
where Egis has
its own marketing
network

4600
colleagues



Sales through our partners





Sales under the brand name Egis through our subsidiaries and representative offices, respectively

Turnover data 2022/2023



Turnover
631.7
million EUR



Egis in Hungary
/based on the number of boxes sold/

1. largest supplier in Hungary



11.1% market share

Turnover data

2022/2023



SALES REVENUE BY MAIN THERAPEUTIC AREAS




158
active ingredients



653
products



193 million
sold boxes
put next to each other:
**Buenos Aires-Budapest-
Tokyo distance**



4600
colleagues



more than
1000 tons
active ingredients/
intermediates



6 billion
number of tablets
and capsules
manufactured



3215
registrations

*Almost 76% of the
world population*